AGP Executive Report
Last update: 11 hours agoCancer Care: The European Commission approved RASONQUE (daraxonrasib), a once-daily oral treatment for adults with metastatic pancreatic cancer after at least one prior systemic therapy. Patient access will depend on national pricing and reimbursement. Lung Cancer: EMA advisers recommended Zybrivo (sintilimab) with chemotherapy as a first-line option for advanced non-squamous lung cancer; European Commission approval is still pending. Rare Conditions: The EU approved Zeydovio (glepaglutide), a twice-weekly treatment for adults with short bowel syndrome, marking the first major European treatment advance for the condition in more than a decade. Regional Health Preparedness: ECDC is preparing to roll out Epi+, a multilingual platform to help nine countries detect and coordinate responses to emerging public-health threats next year. Liechtenstein-Relevant Decisions: EU advisers backed expanded use of Merck’s ENFLONSIA to protect high-risk children from RSV through a second season, and belzutifan plus lenvatinib for advanced kidney cancer after prior immunotherapy. Both recommendations cover Liechtenstein, with European Commission decisions pending.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.